Loading patent…
AssigneeReliance Life Sciences Pvt. Ltd.
InventorsMurali Krishna Addepalli, Vidyadhar Eswar Chandra Gopavaram Reddy
Estimating the term…
This invention relates to the use of short nucleic acid molecules that modulate Aurora-B kinase (AurkB) expression. The invention includes compounds, compositions and methods useful for the modulation of expression and activity of genes involved in the AurkB pathway. In one embodiment, the present invention provides short nucleic acid molecules, such as siRNA, which can be used in treating, preventing, or inhibiting cancer, and any other proliferative disease, trait or condition, which respond to a reduction in AurkB expression in a cell or tissue. Such short nucleic acid molecules can be used alone or in combination with other treatments or therapies, including short nucleic acid molecules that modulate expression of EGFR.
A method for modulating AurkB expression in a cell comprising contacting the cell with a short nucleic acid molecule, wherein the short nucleic acid molecule is up to 30 nucleotides in length, and wherein the short nucleic acid molecule comprises a nucleotide sequence that is 100% complementary to at least 22 consecutive nucleotides in a SEQ ID NO:
A method for modulating AurkB expression in a cell comprising contacting the cell with a short nucleic acid molecule up to 30 nucleotides in length, wherein the short nucleic acid molecule comprises a nucleotide sequence that is complementary to the entire sequence of SEQ ID NO:
A method for treating cancer comprising intratumorally administering to a mammal a short nucleic acid molecule, wherein the short nucleic acid molecule is up to 30 nucleotides in length, and wherein the short nucleic acid molecule comprises a nucleotide sequence that is 100% complementary to at least 22 consecutive nucleotides in SEQ ID NO:
A method for treating cancer comprising intratumorally administering to a mammal a short nucleic acid molecule up to 30 nucleotides in length, and wherein the short nucleic acid molecule comprises a nucleotide sequence that is 100% complementary to the entire sequence of SEQ ID NO:
A method for inhibiting growth of a cancer cell comprising contacting the cell with a short nucleic acid molecule that modulates expression of AurkB, wherein the short nucleic acid molecule is up to 30 nucleotides in length, and wherein the short nucleic acid molecule comprises a nucleotide sequence that is 100% complementary to at least 22 consecutive nucleotides in SEQ ID NO:
A method for inhibiting growth of a cancer cell comprising contacting the cell with a short nucleic acid molecule that modulates expression of AurkB, wherein the short nucleic acid molecule is up to 30 nucleotides in length and wherein the short nucleic acid molecule comprises a nucleotide sequence that is complementary to the entire sequence of SEQ ID NO:
A method of arresting a cancer cell in G2 phase comprising contacting the cell with a short nucleic acid molecule that is up to 30 nucleotides in length, wherein the short nucleic acid molecule comprises a nucleotide sequence that is 100% complementary to at least 22 consecutive nucleotides in SEQ ID NO:
A method of inducing senescence in a cancer cell comprising contacting the cell with a short nucleic acid molecule that is up to 30 nucleotides in length, wherein the short nucleic acid molecule comprises a nucleotide sequence that is 100% complementary to at least 22 consecutive nucleotides in SEQ ID NO:
Dependencies are inferred from the claim text.